Amgen (NASDAQ:AMGN) is expected to report Q4 earnings after the market close on Monday, January 25, with a conference call scheduled for 5 pm ET.
The consensus estimate is $1.13 for EPS and $3.85B for revenue, according to First Call. On the negative side Amgen will continue to be affected by a challenging environment for its Anemia drugs. Regulatory safety restrictions on Anemia drugs and slowing growth in its flagship Anemia drug Enbrel could be a drag on revenue. On the positive side Amgen has an excellent record of EPS growth and margin growth. In addition, the company authorized a $5B increase in its stock repurchase program on December 7 which could help EPS results.
On January 4, RBC Capital said it expects Amgen to report Phase III Dmab data in Q1 for the treatment of bone mets in prostate cancer. The firm thinks the data should be positive and is a buyer into the results. RBC is keeping an Outperform on Amgen shares with a $72 price target.